Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Patient-Centered Outcomes Research Institute | OTHER |
| Advocates | UNKNOWN |
| Bay Cove Human Services | OTHER |
| North Suffolk Mental Health Association |
Not provided
Not provided
Not provided
Not provided
Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings is a research study aimed at developing, implementing, and evaluating a package of interventions specifically designed to reduce COVID-19 and other infectious-disease incidence, hospitalizations, and mortality among staff and adults with Serious Mental Illness and Intellectual and Developmental Disabilities in congregate-living settings.
Persons with Serious Mental Illness (SMI) and Intellectual Disabilities and Developmental Disabilities (ID/DD) are disproportionately vulnerable to COVID-19 for three reasons: (1) Medical vulnerability. Smoking, chronic obstructive pulmonary disease, cardiovascular disease, and diabetes all increase COVID-19 mortality and are about 2-3 times more prevalent among persons with SMI. People with ID/DD suffer higher rates of COVID-19 risk factors, including pre-existing chronic conditions, heart defects, obesity, chronic respiratory problems or lung disease, lower immune function, cancer, and diabetes. (2) Residential vulnerability. The congregate care settings in which many people with SMI and ID/DD live carry many of the same higher risks of COVID-19 transmission currently affecting assisted-living settings and nursing homes across the nation. (3) Health behavior vulnerability. Some people with SMI and ID/DD have cognitive, behavioral, and physical challenges that heighten COVID-19 risk by hampering personal protective practices (PPP) (i.e., hand hygiene, physical distancing, use of face masks). Moreover, the staff who work in congregate care settings are often subject to high rates of exposure, have low socioeconomic status, use public transportation, and lack personal protective equipment. This collection of factors contributes to an extraordinarily high risk of COVID-19 morbidity, and mortality. Despite payment reforms and mandated best practices for COVID-19 for congregate care by the MA Department of Public Health, rates of coronavirus illness for residents with SMI and ID/DD are 8 times higher (12%), and for staff 2 times higher (3.0%), compared to the general population in the surrounding "hot spot" communities (1.5%) selected for this study. This tragic health disparity confirms that key decision-makers lack the knowledge of how to optimally tailor best practices for this highly vulnerable population and the staff who provide their care to effectively reduce their high risk of COVID-19 and COVID-19 related mortality.
The investigators' overall goal is to reduce COVID-19 and other infectious-disease incidence, hospitalizations, and mortality among staff and adults with Serious Mental Illness (SMI) and Intellectual and Developmental Disabilities (ID/DD) in congregate-living settings in Massachusetts. The investigators address 2 comparative-effectiveness questions:
With the goal of prioritizing and resourcing actionable best practices: What is the comparative effectiveness of different types and intensities of five basic preventive interventions-screening, isolation, contact tracing, personal protective practices (PPP) (i.e., hand hygiene, physical distancing, use of face masks), and vaccination-in reducing rates of COVID-19, hospitalizations, and mortality in staff and adult residents with SMI and ID/DD in congregate care settings? Effectiveness Hypothesis: Of the 5 preventive interventions, tailored screening, effective use of isolation, and increased vaccination acceptance will be associated with the greatest reduction of staff and resident COVID-19 rates and related hospitalizations.
With the goal of effectively implementing best practices: What is the most effective implementation strategy to reduce rates of COVID-19 in congregate care settings for persons with SMI and ID/DD: (1) Tailored Best Practices (TBP) specifically adapted for staff and residents with SMI and ID/DD in congregate living settings or (2) Generic Best-Practices (GBP) consisting of state and federal standard guidelines for all congregate care settings? Implementation Hypothesis: TBP will be associated with greater implementation fidelity and lower staff and resident rates of COVID-19 and hospitalization than GBP.
To test these hypotheses, the investigators will pursue three Aims:
Aim 1: The investigators will synthesize existing data collected by the six provider organizations on (1) rates of COVID-19, hospitalization, and mortality and (2) use of screening, isolation, contact tracing, PPP, and vaccination in 400 group homes for SMI and ID/DD. The investigators will also collect qualitative data through surveys and virtual focus groups on the experience of staff and residents, and on barriers and facilitators to implementing recommended practices.
Aim 2: The investigators will determine the comparative effectiveness of different COVID-19 preventive practices (screening, isolation, contact tracing, use of PPP, vaccination) by populating a validated simulation model and engage decision makers and stakeholders in selecting priorities for best practices. The investigators will apply the Clinical and Economic Analysis of COVID-19 Interventions (CEACOV), a COVID-19 simulation model that has already been developed and validated, to simulate the 2,050 residents and 3,300 staff of the 400 group homes for persons with SMI and ID/DD in the study. The investigators will compare the effectiveness of different types, intensities, and combinations of the five identified interventions: screening, isolation, contact tracing, PPP, and vaccination.
On completion of the simulation modeling at month 3, the investigators will convene a COVID-19 Quality Improvement Collaborative (CQIC) Virtual Summit including consumers, providers, advocates, and key decision makers, during which the investigators will summarize the results of the comparative effectiveness simulation model and present alternative scenarios demonstrating the impact of increasing or decreasing amounts or combinations of various practices. The CQIC Virtual Summit and 1-2 additional brief virtual meetings will result in recommendations for a final prioritized set of actionable and feasible Tailored Best Practices (TBP) for implementation. The CQIC will review and adapt relevant COVID-19 training materials and finalize a TBP implementation package.
Aim 3: The investigators will employ a cluster randomized trial design with 200 group homes randomized to implementation of "Tailored Best Practices" (TBP) compared to 200 group homes randomized to "Generic Best Practices" (GBP). The investigators will engage in a three-month observational pre-randomization period to assess the baseline use of preventive practices and rates of COVID in each group home to better isolate the effect of the introduction of the TBP intervention. The investigators have also incorporated a 3-month implementation phase in order to accommodate implementing the TBP intervention with fidelity across 200 group homes during the same time period. The best practice implementation fidelity and COVID-19 incidence are co-primary outcomes with group home as the unit of analysis. Within each site, the investigators will engage in repeated measurement of these outcomes across 6 time points (Baseline, 3, 6, 9, 12, and 15 months) so that time effects (observed and latent) can be modeled precisely in the presence of any fluctuations in incidence over time.
By month 16 of the project, the investigators will know the effectiveness of the Tailored Best Practices (TBP) implementation for a diverse array of state-supported group homes for SMI and ID/DD with broad generalizability to similar settings across the nation that will be broadly distributed through dissemination materials at the end of the project.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Generic Best Practices (GBP) | Active Comparator | The ~200 group homes randomized into this arm will receive the Generic Best Practices (GBP) intervention package as part of routine training activities. GBP consists of state and federal standard guidelines for COVID-19 mitigation for all congregate living settings. |
|
| Tailored Best Practices (TBP) | Experimental | The ~200 group homes randomized into this arm will receive the Tailored Best Practices (TBP) intervention package as part of routine training activities. TBP consists of COVID-19 mitigation measures specifically adapted for staff and residents with SMI and ID/DD in congregate living settings. Sites in this arm will receive coaching specific to the setting, staff, and residents. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Generic Best Practices | Behavioral | GBP consists of (1) Massachusetts Executive Office of Health and Human Services distribution of standard guidelines and policies for public health prevention and management of COVID and (2) standard virtual training of the staff of the group homes in these generic COVID-19 prevention practices including recommended use of hand washing, use of PPE, and symptom-triggered screening. Group homes randomized to this intervention will receive standard recommended and fully vetted best practices with respect to preventing and managing COVID-19 based on recommendations by the CDC and on consultation with leading national experts in infectious disease working with the Commonwealth of Massachusetts. The control condition does not represent inferior or substandard practice. As findings occur and as policy leads to adjustments in recommendations during the course of the study, the GBP condition will incorporate recommendations that are appropriate and up-to-date with CDC and state policy. |
| Measure | Description | Time Frame |
|---|---|---|
| New COVID-19 Group Home Incidence | New laboratory-confirmed COVID-19 cases among residents and staff. Measured as new cases per 100 person-months. | The outcome was measured at baseline, 3-, 6-, 9-, 12-, and 15-months post-baseline. |
| Best Practices Fidelity | Best Practices Fidelity is measured by the COVID-19 Best Practices Fidelity Measure developed for this project and refined with input from stakeholders on relevant COVID-19-prevention policies (e.g. number of staff and residents participating in recommended screening, masking, hand washing, and vaccination in the group homes). The Fidelity scale was developed by operationally defining 2-4 items to assess each measure, with items scored on a 5- to 6-point continuum with a rating of 5 or 6 indicating full adherence to the fidelity standard and 1 indicating complete lack of adherence. A home's overall, continuous fidelity score was calculated by averaging measure-specific scores by time period. Each active measure was given equal weight. The percentage scores for each of these measures were then averaged together. The overall fidelity score ranged from a low of 20% (1 out of 5 on each item) to a high of 100% (5 out of 5 on each item). | The outcome will be measured at baseline, 3-, 6-, 9-, 12-, and 15-months post-baseline. |
| Full COVID-19 Vaccination Status Among Residents | This outcome measure reflects the number of group home (GH) residents who were not fully vaccinated at the beginning of the study (by March 31, 2021) but became fully vaccinated during the study period. Individual-level dates of COVID-19 vaccinations were obtained from records maintained by GH organizations. A person was considered to be fully vaccinated when they received the full dosage of initial immunization(s) as recommended by the CDC during the study, either two initial doses of the Pfizer or Moderna vaccine or one dose of the Johnson & Johnson vaccine. Baseline vaccination rates were established from January 1, 2021, to March 31, 2021. | Assessed from April 1 to the date of vaccination (up to June 30, 2022), up to 15 months for each participant. |
| Full COVID-19 Vaccination Status Among Staff |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
1. All congregate care homes in Massachusetts not operated by any of the public-sector community-based human service organizations mentioned above
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Stephen J Bartels, MD, MS | Massachusetts General Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38926810 | Derived | Bartels S, Levison JH, Trieu HD, Wilson A, Krane D, Cheng D, Xie H, Donelan K, Bird B, Shellenberger K, Cella E, Oreskovic NM, Irwin K, Aschbrenner K, Fathi A, Gamse S, Holland S, Wolfe J, Chau C, Adejinmi A, Langlois J, Reichman JL, Iezzoni LI, Skotko BG. Tailored vs. General COVID-19 prevention for adults with mental disabilities residing in group homes: a randomized controlled effectiveness-implementation trial. BMC Public Health. 2024 Jun 26;24(1):1705. doi: 10.1186/s12889-024-18835-w. | |
| 38915130 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
No group homes enrolled in the study were excluded before assignment to groups.
Unit of recruitment and analysis was Group Home (GH). Recruitment occurred between 11/2020-12/2020. CEOs of 6 provider organizations provided letters of commitment to participate in the trial and written consent for their sites to be included. All GHs were included other than those with residents <=18 years of age and Acquired Brain Injury homes. No individual participants were recruited, provided informed consent, or were enrolled in the study.
| ID | Title | Description |
|---|---|---|
| FG000 | Generic Best Practices (GBP) | The 207 group homes randomized into this arm received the Generic Best Practices (GBP) intervention package as part of routine training activities. GBP consisted of state and federal standard guidelines for COVID-19 mitigation for all congregate living settings. Generic Best Practices: GBP consisted of (1) Massachusetts Executive Office of Health and Human Services distribution of standard guidelines and policies for public health prevention and management of COVID and (2) standard virtual training of the staff of the group homes in these generic COVID-19 prevention practices including recommended use of hand washing, use of PPE, and symptom-triggered screening. Group homes randomized to this intervention received standard recommended and fully vetted best practices with respect to preventing and managing COVID-19 based on recommendations by the CDC and on consultation with leading national experts in infectious disease working with the Commonwealth of Massachusetts. The control condition did not represent inferior or substandard practice. As findings occurred and as policy led to adjustments in recommendations during the course of the study, the GBP condition incorporated recommendations that were appropriate and up-to-date with CDC and state policy. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Apr 5, 2022 | Mar 22, 2023 |
Not provided
| OTHER |
| Open Sky Community Services | UNKNOWN |
| Riverside Community Care, Inc. | UNKNOWN |
| Dartmouth College | OTHER |
| Vinfen | INDUSTRY |
The investigators will employ a cluster-randomized trial design with ~200 group homes randomized to the implementation of "Tailored Best Practices" (TBP) compared to ~200 group homes randomized to "Generic Best Practices" (GBP). Randomization will occur at the level of the group home stratified by group home type (SMI versus ID/DD), incident COVID-19 infection in the staff and residents (high incidence versus low incidence), and race/ethnicity (proportion non-Hispanic Caucasian versus other). TBP and GBP will be delivered within each agency as part of routine training activities. TBP sites will receive coaching specific to the setting, staff, and residents. The best practice implementation fidelity (i.e. staff and residents participating in recommended screening, isolating, contact tracing, PPP protocols, and vaccine acceptance), and COVID-19 incidence are co-primary outcomes with group home as the unit of analysis. The outcomes will be assessed at baseline, 3, 6, 9, 12, and 15 months.
Not provided
Not provided
Not provided
Not provided
|
|
| Tailored Best Practices | Behavioral | TBP consists of optimized, tailored, and highly specific COVID-19 best practices and training materials specific to the setting, staff, and residents with SMI and ID/DD in congregate living settings based on the comparative effectiveness of different types, intensities, and combinations of COVID-19 prevention practices (screening, isolation, contact tracing, use of PPP, vaccination) specifically modeled for residents and staff of congregate living settings for people with ID/DD and SMI derived by a simulation model. Results from this modeling process will be provided to stakeholders to support decision makers in prioritizing resources and practices with the greatest impact on reducing COVID-19 tailored for people with SMI and ID/DD in congregate living settings. This process to determine the content of TBP will occur as part of this study prior to randomization. |
|
|
This outcome measure reflects the number of group home (GH) staff who were not fully vaccinated at the beginning of the study (by March 31, 2021) but became fully vaccinated during the study period. Individual-level dates of COVID-19 vaccinations were obtained from records maintained by GH organizations. A person was considered to be fully vaccinated when they received the full dosage of initial immunization(s) as recommended by the CDC during the study, either two initial doses of the Pfizer or Moderna vaccine or one dose of the Johnson & Johnson vaccine. Baseline vaccination rates were established from January 1, 2021, to March 31, 2021. |
| Assessed from April 1 to the date of vaccination (up to June 30, 2022), up to 15 months for each participant. |
| Derived |
| Becker JE, Shebl FM, Losina E, Wilson A, Levison JH, Donelan K, Fung V, Trieu H, Panella C, Qian Y, Kazemian P, Bird B, Skotko BG, Bartels S, Freedberg KA. Using simulation modeling to inform intervention and implementation selection in a rapid stakeholder-engaged hybrid effectiveness-implementation randomized trial. Implement Sci Commun. 2024 Jun 24;5(1):70. doi: 10.1186/s43058-024-00593-w. |
| 38597249 | Derived | Constantin AM, Noertjojo K, Sommer I, Pizarro AB, Persad E, Durao S, Nussbaumer-Streit B, McElvenny DM, Rhodes S, Martin C, Sampson O, Jorgensen KJ, Bruschettini M. Workplace interventions to reduce the risk of SARS-CoV-2 infection outside of healthcare settings. Cochrane Database Syst Rev. 2024 Apr 10;4(4):CD015112. doi: 10.1002/14651858.CD015112.pub3. |
| 37938475 | Derived | Fung V, Levison JH, Wilson A, Cheng D, Chau C, Krane D, Trieu HD, Irwin K, Cella E, Bird B, Shellenberger K, Silverman P, Batson J, Fathi A, Gamse S, Wolfe J, Holland S, Donelan K, Samuels R, Becker JE, Freedberg KA, Reichman JL, Keller T, Tsai AC, Hsu J, Skotko BG, Bartels S. COVID-19-Related Outcomes Among Group Home Residents with Serious Mental Illness in Massachusetts in the First Year of the Pandemic. Adm Policy Ment Health. 2024 Jan;51(1):60-68. doi: 10.1007/s10488-023-01311-9. Epub 2023 Nov 8. |
| 36539061 | Derived | Levison JH, Krane D, Donelan K, Aschbrenner K, Trieu HD, Chau C, Wilson A, Oreskovic NM, Irwin K, Iezzoni LI, Xie H, Samuels R, Silverman P, Batson J, Fathi A, Gamse S, Holland S, Wolfe J, Shellenberger K, Cella E, Bird B, Skotko BG, Bartels S. Best practices to reduce COVID-19 in group homes for individuals with serious mental illness and intellectual and developmental disabilities: Protocol for a hybrid type 1 effectiveness-implementation cluster randomized trial. Contemp Clin Trials. 2023 Feb;125:107053. doi: 10.1016/j.cct.2022.107053. Epub 2022 Dec 17. |
| FG001 | Tailored Best Practices (TBP) | The 208 group homes randomized into this arm received the Tailored Best Practices (TBP) intervention package as part of routine training activities. TBP consisted of COVID-19 mitigation measures specifically adapted for staff and residents with SMI and ID/DD in congregate living settings. Sites in this arm received coaching specific to the setting, staff, and residents. Tailored Best Practices: TBP consisted of optimized, tailored, and highly specific COVID-19 best practices and training materials specific to the setting, staff, and residents with SMI and ID/DD in congregate living settings based on the comparative effectiveness of different types, intensities, and combinations of COVID-19 prevention practices (screening, isolation, contact tracing, use of PPP, vaccination) specifically modeled for residents and staff of congregate living settings for people with ID/DD and SMI derived by a simulation model. There were four main components to Tailored Best Practices: Measurement, Feedback, and House Plans; Motivational Interviewing; Interactive Education; and Trusted Messengers. |
| Residents (Vaccination Analysis) | The sample used for vaccination analysis was limited to individuals who were not fully vaccinated at baseline. This is a subsample of the sample used for the COVID-19 incidence and fidelity primary analyses. |
|
| Staff (Vaccination Analysis) | The sample used for vaccination analysis was limited to individuals who were not fully vaccinated at baseline. This is a subsample of the sample used for the COVID-19 incidence and fidelity primary analyses. |
|
| COMPLETED |
|
| NOT COMPLETED |
|
Due to our project design, 2,345 participants had delayed entry to the study. As the unit of randomization was the group home and not individual participants, this was a dynamic sample. The Participant Flow reflects all participants who entered the study at any point. The Baseline Analysis Population reflects only those participants present during the baseline period of the study.
| ID | Title | Description |
|---|---|---|
| BG000 | Generic Best Practices (GBP) | The 207 group homes randomized into this arm received the Generic Best Practices (GBP) intervention package as part of routine training activities. GBP consisted of state and federal standard guidelines for COVID-19 mitigation for all congregate living settings. Generic Best Practices: GBP consisted of (1) Massachusetts Executive Office of Health and Human Services distribution of standard guidelines and policies for public health prevention and management of COVID and (2) standard virtual training of the staff of the group homes in these generic COVID-19 prevention practices including recommended use of hand washing, use of PPE, and symptom-triggered screening. Group homes randomized to this intervention received standard recommended and fully vetted best practices with respect to preventing and managing COVID-19 based on recommendations by the CDC and on consultation with leading national experts in infectious disease working with the Commonwealth of Massachusetts. The control condition did not represent inferior or substandard practice. As findings occurred and as policy led to adjustments in recommendations during the course of the study, the GBP condition incorporated recommendations that were appropriate and up-to-date with CDC and state policy. |
| BG001 | Tailored Best Practices (TBP) | The 208 group homes randomized into this arm received the Tailored Best Practices (TBP) intervention package as part of routine training activities. TBP consisted of COVID-19 mitigation measures specifically adapted for staff and residents with SMI and ID/DD in congregate living settings. Sites in this arm received coaching specific to the setting, staff, and residents. Tailored Best Practices: TBP consisted of optimized, tailored, and highly specific COVID-19 best practices and training materials specific to the setting, staff, and residents with SMI and ID/DD in congregate living settings based on the comparative effectiveness of different types, intensities, and combinations of COVID-19 prevention practices (screening, isolation, contact tracing, use of PPP, vaccination) specifically modeled for residents and staff of congregate living settings for people with ID/DD and SMI derived by a simulation model. There were four main components to Tailored Best Practices: Measurement, Feedback, and House Plans; Motivational Interviewing; Interactive Education; and Trusted Messengers. |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Group homes |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean | Standard Deviation | years | Group homes |
|
| |||||||||||||||||||
| Sex/Gender, Customized | Mean | Standard Deviation | percentage of participants | Group homes |
| ||||||||||||||||||||
| Race/Ethnicity, Customized | Mean | Standard Deviation | percentage of participants | Group homes |
| ||||||||||||||||||||
| Division | Count of Units | Group homes | Group homes |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | New COVID-19 Group Home Incidence | New laboratory-confirmed COVID-19 cases among residents and staff. Measured as new cases per 100 person-months. | One group home in the GBP arm closed between the 6- and 9-month follow-up periods. The BL sample size here is different than the BL descriptive table. For the BL descriptive table, we assigned participants on an intent-to-treat basis in order to avoid overlap. However, for our analysis, participant allocation was based on the home that they lived or worked in during the study period. Since some staff worked in multiple homes across both arms, the samples are not mutually exclusive. | Posted | Mean | 95% Confidence Interval | New COVID-19 cases per 100 person-months | The outcome was measured at baseline, 3-, 6-, 9-, 12-, and 15-months post-baseline. | Group home | Group home |
|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Best Practices Fidelity | Best Practices Fidelity is measured by the COVID-19 Best Practices Fidelity Measure developed for this project and refined with input from stakeholders on relevant COVID-19-prevention policies (e.g. number of staff and residents participating in recommended screening, masking, hand washing, and vaccination in the group homes). The Fidelity scale was developed by operationally defining 2-4 items to assess each measure, with items scored on a 5- to 6-point continuum with a rating of 5 or 6 indicating full adherence to the fidelity standard and 1 indicating complete lack of adherence. A home's overall, continuous fidelity score was calculated by averaging measure-specific scores by time period. Each active measure was given equal weight. The percentage scores for each of these measures were then averaged together. The overall fidelity score ranged from a low of 20% (1 out of 5 on each item) to a high of 100% (5 out of 5 on each item). | Best Practices Fidelity was measured using a voluntary survey completed only by group home Program Directors who consented to participate at each time point. Participant counts are limited to individuals in homes whose Program Directors contributed survey responses during each time period. Participants were assigned to homes based on where they lived or worked during the study period. Since some staff worked in multiple homes across both arms, the samples are not mutually exclusive. | Posted | Mean | 95% Confidence Interval | score on a scale | The outcome will be measured at baseline, 3-, 6-, 9-, 12-, and 15-months post-baseline. | Group home | Group home |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Full COVID-19 Vaccination Status Among Residents | This outcome measure reflects the number of group home (GH) residents who were not fully vaccinated at the beginning of the study (by March 31, 2021) but became fully vaccinated during the study period. Individual-level dates of COVID-19 vaccinations were obtained from records maintained by GH organizations. A person was considered to be fully vaccinated when they received the full dosage of initial immunization(s) as recommended by the CDC during the study, either two initial doses of the Pfizer or Moderna vaccine or one dose of the Johnson & Johnson vaccine. Baseline vaccination rates were established from January 1, 2021, to March 31, 2021. | Residents with SMI or ID/DD who were not fully vaccinated by March 31, 2021. | Posted | Count of Participants | Participants | Assessed from April 1 to the date of vaccination (up to June 30, 2022), up to 15 months for each participant. |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Primary | Full COVID-19 Vaccination Status Among Staff | This outcome measure reflects the number of group home (GH) staff who were not fully vaccinated at the beginning of the study (by March 31, 2021) but became fully vaccinated during the study period. Individual-level dates of COVID-19 vaccinations were obtained from records maintained by GH organizations. A person was considered to be fully vaccinated when they received the full dosage of initial immunization(s) as recommended by the CDC during the study, either two initial doses of the Pfizer or Moderna vaccine or one dose of the Johnson & Johnson vaccine. Baseline vaccination rates were established from January 1, 2021, to March 31, 2021. | Staff who were not fully vaccinated by March 31, 2021. | Posted | Count of Participants | Participants | Assessed from April 1 to the date of vaccination (up to June 30, 2022), up to 15 months for each participant. |
|
Adverse event data were collected from baseline through 15-month follow-up, totaling 1 year and 6 months.
The adverse event data collected for this study includes COVID-19-related events. All deaths and hospitalizations in the data were caused by COVID-19, meaning deaths and hospitalization unrelated to COVID-19 were not included. Furthermore, the adverse events data only include adverse events for group home residents and not for group home staff.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Generic Best Practices (GBP) | The 207 group homes randomized into this arm received the Generic Best Practices (GBP) intervention package as part of routine training activities. GBP consisted of state and federal standard guidelines for COVID-19 mitigation for all congregate living settings. Generic Best Practices: GBP consisted of (1) Massachusetts Executive Office of Health and Human Services distribution of standard guidelines and policies for public health prevention and management of COVID and (2) standard virtual training of the staff of the group homes in these generic COVID-19 prevention practices including recommended use of hand washing, use of PPE, and symptom-triggered screening. Group homes randomized to this intervention received standard recommended and fully vetted best practices with respect to preventing and managing COVID-19 based on recommendations by the CDC and on consultation with leading national experts in infectious disease working with the Commonwealth of Massachusetts. The control condition did not represent inferior or substandard practice. As findings occurred and as policy led to adjustments in recommendations during the course of the study, the GBP condition incorporated recommendations that were appropriate and up-to-date with CDC and state policy. | 1 | 2,059 | 16 | 2,059 | 0 | 2,059 |
| EG001 | Tailored Best Practices (TBP) | The 208 group homes randomized into this arm received the Tailored Best Practices (TBP) intervention package as part of routine training activities. TBP consisted of COVID-19 mitigation measures specifically adapted for staff and residents with SMI and ID/DD in congregate living settings. Sites in this arm received coaching specific to the setting, staff, and residents. Tailored Best Practices: TBP consisted of optimized, tailored, and highly specific COVID-19 best practices and training materials specific to the setting, staff, and residents with SMI and ID/DD in congregate living settings based on the comparative effectiveness of different types, intensities, and combinations of COVID-19 prevention practices (screening, isolation, contact tracing, use of PPP, vaccination) specifically modeled for residents and staff of congregate living settings for people with ID/DD and SMI derived by a simulation model. There were four main components to Tailored Best Practices: Measurement, Feedback, and House Plans; Motivational Interviewing; Interactive Education; and Trusted Messengers. | 1 | 1,777 | 11 | 1,777 | 0 | 1,777 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Inpatient hospitalization due to COVID-19 infection | Infections and infestations | Systematic Assessment |
|
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Stephen Bartels | The Mongan Institute at Massachusetts General Hospital | 617-726-5213 | sjbartels@mgh.harvard.edu |
| Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Mar 22, 2023 | Mar 22, 2023 | SAP_001.pdf |
| ID | Term |
|---|---|
| D008607 | Intellectual Disability |
| D002658 | Developmental Disabilities |
| D001523 | Mental Disorders |
| D000086382 | COVID-19 |
| D018352 | Coronavirus Infections |
| ID | Term |
|---|---|
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D065886 | Neurodevelopmental Disorders |
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
| D014777 | Virus Diseases |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C009524 | tributyl phosphate |
Not provided
Not provided
Not provided
| Group homes |
|
|
| Group homes |
|
|
| Group homes |
|
|
|
| 3-month follow-up |
|
|
| 6-month follow-up |
|
|
| 9-month follow-up |
|
|
| 12-month follow-up |
|
|
| 15-month follow-up |
|
|
| Superiority |
The point estimates for intervention main effect, intervention by linear time effect, and for intervention by time^2 interaction effect are described in the paper "Tailored vs. General COVID-19 prevention for adults with mental disabilities residing in group homes: a randomized controlled effectiveness-implementation trial" by Bartels S, Levison JH, Trieu HD, et al., published in 2024 in BMC Public Health, doi:10.1186/s12889-024-18835-w. |
| OG001 | Tailored Best Practices (TBP) | The 208 group homes randomized into this arm received the Tailored Best Practices (TBP) intervention package as part of routine training activities. TBP consisted of COVID-19 mitigation measures specifically adapted for staff and residents with SMI and ID/DD in congregate living settings. Sites in this arm received coaching specific to the setting, staff, and residents. Tailored Best Practices: TBP consisted of optimized, tailored, and highly specific COVID-19 best practices and training materials specific to the setting, staff, and residents with SMI and ID/DD in congregate living settings based on the comparative effectiveness of different types, intensities, and combinations of COVID-19 prevention practices (screening, isolation, contact tracing, use of PPP, vaccination) specifically modeled for residents and staff of congregate living settings for people with ID/DD and SMI derived by a simulation model. There were four main components to Tailored Best Practices: Measurement, Feedback, and House Plans; Motivational Interviewing; Interactive Education; and Trusted Messengers. |
|
|
|
| OG001 | Tailored Best Practices (TBP) | The ~200 group homes randomized into this arm will receive the Tailored Best Practices (TBP) intervention package as part of routine training activities. TBP consists of COVID-19 mitigation measures specifically adapted for staff and residents with SMI and ID/DD in congregate living settings. Sites in this arm will receive coaching specific to the setting, staff, and residents. Tailored Best Practices: TBP consists of optimized, tailored, and highly specific COVID-19 best practices and training materials specific to the setting, staff, and residents with SMI and ID/DD in congregate living settings based on the comparative effectiveness of different types, intensities, and combinations of COVID-19 prevention practices (screening, isolation, contact tracing, use of PPP, vaccination) specifically modeled for residents and staff of congregate living settings for people with ID/DD and SMI derived by a simulation model. Results from this modeling process will be provided to stakeholders to support decision makers in prioritizing resources and practices with the greatest impact on reducing COVID-19 tailored for people with SMI and ID/DD in congregate living settings. This process to determine the content of TBP will occur as part of this study prior to randomization. |
|
|
|
| OG001 | Tailored Best Practices (TBP) | The ~200 group homes randomized into this arm will receive the Tailored Best Practices (TBP) intervention package as part of routine training activities. TBP consists of COVID-19 mitigation measures specifically adapted for staff and residents with SMI and ID/DD in congregate living settings. Sites in this arm will receive coaching specific to the setting, staff, and residents. Tailored Best Practices: TBP consists of optimized, tailored, and highly specific COVID-19 best practices and training materials specific to the setting, staff, and residents with SMI and ID/DD in congregate living settings based on the comparative effectiveness of different types, intensities, and combinations of COVID-19 prevention practices (screening, isolation, contact tracing, use of PPP, vaccination) specifically modeled for residents and staff of congregate living settings for people with ID/DD and SMI derived by a simulation model. Results from this modeling process will be provided to stakeholders to support decision makers in prioritizing resources and practices with the greatest impact on reducing COVID-19 tailored for people with SMI and ID/DD in congregate living settings. This process to determine the content of TBP will occur as part of this study prior to randomization. |
|
|
|
|
|
|
|
|